ALT - Altimmune, Inc.
| Previous Close | 0.510 |
| Open | 0.535 |
| Bid | 0.372 x 1000 |
| Ask | 0.380 x 1000 |
| Day's Range | 0.450 - 0.535 |
| 52 Week Range | 0.399 - 3.160 |
| Volume | 3,017,983 |
| Avg. Volume | 1,019,868 |
| Market Cap | 15.799M |
| Beta | 1.32 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.210 |
| Earnings Date | Aug 8, 2018 - Aug 13, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | 2017-01-20 |
| 1y Target Est | 4.00 |
- GlobeNewswire•5 days ago
Altimmune Restructures Financing Agreement with Majority of the Remaining Series B Investors
Altimmune, Inc. (ALT), a clinical-stage immunotherapeutics company focused on preventing infectious diseases, today announced it has entered into agreements with substantially all of the remaining investors in its Series B Financing to restructure and terminate the previous arrangements. Under terms of these new agreements, long term investors Novartis Ventures, HealthCap, Truffle Capital, Fidelis Capital and Bonaventure Capital have partnered with Altimmune to receive common shares as repayment of the final installment of the Series B preferred stock and to terminate all outstanding warrants held by them. Together with the restructuring announced on June 22, approximately 97% of the Series B Financing has now been restructured and, as of July 17, no shares of the Company’s Series B preferred stock will be outstanding and only 75,995 of the associated warrants will remain outstanding.
- GlobeNewswire•7 days ago
Altimmune Appoints Mitchel Sayare as Executive Chairman of the Board, and Adds José Ochoa to Its Leadership Team as Chief Business Officer
Dr. Sayare originally joined PharmAthene’s Board of Directors in April 2010. Dr. Sayare will work closely with management to effect important changes in strategic focus, financing efforts and partnering initiatives.
- GlobeNewswire•24 days ago
Altimmune Restructures Financing Agreement
Altimmune, Inc. (ALT), a clinical-stage immunotherapeutics company focused on preventing infectious diseases, today announced it has entered into an agreement with the lead investor and one other investor in its Series B Financing to restructure and terminate the previous arrangements. Under terms of the new agreement, these two investors, who collectively held approximately 68% of the outstanding shares of Series B preferred stock and associated warrants, will receive cash instead of common shares as repayment of the final two installments of the Series B preferred stock. Additionally, the investors will receive a combination of cash and common stock to terminate all outstanding warrants held by them. A portion of the cash will be in the form of a short-term note, which may be converted into shares of common stock at the election of the holder thereof upon the occurrence of certain specified events of default.
- ACCESSWIRE•last month
Stock Performance Review on Alder Biopharma and Three Other Biotech Stocks
LONDON, UK / ACCESSWIRE / June 11, 2018 / If you want a free Stock Review on ALDR sign up now at www.wallstequities.com/registration. Gains were broad based as seven out of nine sectors finished the trading session in green. WallStEquities.com has initiated research reports on the following Biotechnology stocks: Alder Biopharmaceuticals Inc. (NASDAQ: ALDR), Alexion Pharmaceuticals Inc. (NASDAQ: ALXN), Alnylam Pharmaceuticals Inc. (NASDAQ: ALNY), and Altimmune Inc. (NASDAQ: ALT).
- Reuters•last month
U.S. hedge fund Hudson Bay to open London office - sources
U.S. hedge fund Hudson Bay Capital is opening an office in Britain to expand its European trading book, two sources told Reuters on Tuesday. Hudson Bay, which runs $2.8 billion in assets across equity, credit and other assets, has hired a team of three for its new London base and plans to add more staff, the sources with direct knowledge of the matter said. Other U.S. hedge funds are have also increased investment in Europe, including high-profile activists such as Elliott Advisers, amid increased competition and less attractive valuations at home.
- Reuters•last month
U.S. hedge fund Hudson Bay to open London office -sources
U.S. hedge fund Hudson Bay Capital is opening an office in Britain to expand its European trading book, two sources told Reuters on Tuesday. Hudson Bay, which runs $2.8 billion in assets across equity, credit and other assets, has hired a team of three for its new London base and plans to add more staff, the sources with direct knowledge of the matter said. Other U.S. hedge funds are have also increased investment in Europe, including high-profile activists such as Elliott Advisers, amid increased competition and less attractive valuations at home.
- Simply Wall St.•2 months ago
Does Altimmune Inc’s (NASDAQ:ALT) CEO Salary Reflect Performance?
Leading Altimmune Inc (NASDAQ:ALT) as the CEO, Bill Enright took the company to a valuation of US$9.21M. Understanding how CEOs are incentivised to run and grow their company is anRead More...
- American City Business Journals•2 months ago
Gaithersburg biotech faces threat of stock delisting
The company's stock price has been trading too low for the Nasdaq's liking.
- GlobeNewswire•2 months ago
Altimmune Announces First Quarter 2018 Financial Results and Provides Corporate Update
Conference call and webcast scheduled for tomorrow, May 16 at 8:30am ET. GAITHERSBURG, Md., May 15, 2018-- Altimmune, Inc., a clinical-stage immunotherapeutics company, today announced financial results ...
- Simply Wall St.•2 months ago
Who Are The Major Shareholders Of Altimmune Inc (NASDAQ:ALT)?
In this article, I’m going to take a look at Altimmune Inc’s (NASDAQ:ALT) latest ownership structure, a non-fundamental factor which is important, but remains a less discussed subject among investors.Read More...
- GlobeNewswire•2 months ago
Altimmune to Announce First Quarter 2018 Financial Results on May 16
GAITHERSBURG, Md., May 08, 2018-- Altimmune, Inc., a clinical-stage immunotherapeutics company, today announced that it will announce financial results for the first quarter ended March 31, 2018 before ...
- ACCESSWIRE•3 months ago
Free Research Report as ChemoCentryx’s Quarterly Revenues Zoomed More than 1000%; Turned Profitable Y-O-Y
LONDON, UK / ACCESSWIRE / April 19, 2018 / Active-Investors.com has just released a free earnings report on ChemoCentryx, Inc. (NASDAQ: CCXI). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=CCXI. The Company reported its fourth quarter fiscal 2017 and full fiscal year 2017 operating and financial results on March 14, 2018.
- Market Exclusive•4 months ago
Here’s What’s Moving Esperion And Altimmune, Inc.
Esperion (NASDAQ:ESPR) was one of the midweek movers in the biotechnology space this week, with the company putting out data related to one of its lead investigative assets and picking up some considerable volatility on the back of the release. For those not familiar with Esperion, the company is trying to develop a drug called […] The post Here’s What’s Moving Esperion And Altimmune, Inc. appeared first on Market Exclusive.
- Simply Wall St.•6 months ago
Should You Be Concerned About Altimmune Inc’s (NASDAQ:ALT) Investors?
In this article, I will take a quick look at Altimmune Inc’s (NASDAQ:ALT) recent ownership structure – an unconventional investing subject, but an important one. A company’s ownership structure isRead More...
- Simply Wall St.•7 months ago
Is Altimmune Inc’s (NASDAQ:ALT) CEO Paid At A Competitive Rate?
Leading Altimmune Inc (NASDAQ:ALT) as the CEO, Bill Enright took the company to a valuation of $27.35M. Understanding how CEOs are incentivised to run and grow their company is anRead More...
